Clinical trials: No Disease
Sore Throat
A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat
The purpose of this study was to evaluate no less therapeutic efficacy and safety of the Angal, lozenges [Menthol], 1 mg + 5 mg (Sandoz dd, Slovenia) compared to ANTI-ANGIN® FORMULA, lozenges, 0,2 mg + 2 mg + 50 mg (LLC…
- Trial name
- NCT03095521
- Testing
- Angal, lozenges [menthol],, ANTI-ANGIN® FORMULA
- Where
- 14 sites in Russia
- Volunteers
- 228 people
- Sponsor
- Sandoz
Leukemia, Myeloid, Acute
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.
- Trial name
- NCT03823352
- Testing
- Antroquinonol
- Where
- 2 sites in Russia
- Volunteers
- 12 people
- Sponsor
- Golden Biotechnology Corporation
Bladder Cancer
Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer and may have fewer side effects and improve recovery.
- Trial name
- NCT00003725
- Testing
- valrubicin, conventional surgery
- Where
- 53 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Anthra Pharmaceuticals
Nasal Polyps
A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
This study will evaluate the effectiveness and safety of MFNS in improving nasal congestion/obstruction and in reducing bilateral nasal polyps.
- Trial name
- NCT01386125
- Testing
- Mometasone Furoate Nasal Spray (MFNS)
- Volunteers
- 748 people
- Sponsor
- Organon and Co
Anxiety, Anxiety Disorders
Generalized Anxiety Disorder Adjunct Study
This study is being carried out to see if extended release quetiapine fumarate (Seroquel®XL) when added to standard selective serotonin reuptake inhibitor (SSRI) / serotonin-norepinephrine reuptake inhibitor (SNRI) therapy is…
- Conditions
- Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
- Trial name
- NCT00534599
- Testing
- quetiapine fumarate XR
- Where
- 53 sites in United States
- Volunteers
- 409 people
- Sponsor
- AstraZeneca
Blindness and Low Vision
A Pilot Study Comparing Performance of Blind Participants on 12 Tasks, With and Without the ARIA Device
Summary The environment in which we live, play and travel is primarily built by and for people with sight. Navigating the sighted world with blindness can be exhausting, as it involves disorientation, social isolation, increased…
- Trial name
- NCT06477809
- Testing
- ARIA Glasses ( Augmented Reality in Audio )
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- ARIA Research Pty Ltd
Cystic Fibrosis
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual…
- Trial name
- NCT05076149
- Testing
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA
- Where
- 170 sites in United States, Australia and 18 more
- Volunteers
- 597 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Ankylosing Spondylitis
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
The objective of this study is to determine the difference in the annual incidence rate of uveitis attacks in participants with ankylosing spondylitis (AS) before start initial anti-TNF therapy and after treatment with golimumab…
- Trial name
- GO-EASY (NCT01668004)
- Testing
- Golimumab
- Volunteers
- 101 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory…
- Trial name
- NCT04729387
- Testing
- Alpelisib, Olaparib, Paclitaxel
- Where
- 93 sites in United States, Argentina and 24 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Urolithiasis, Stones, Kidney
Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology
The goal of this clinical trial is to compare Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System and standard ureteroscopy (URS) with laser lithotripsy for the treatment of urolithiasis.
- Conditions
- Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
- Trial name
- TRUST (NCT07101809)
- Testing
- Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System, Standard Ureteroscopy (URS)
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- Calyxo, Inc.
Iron-Deficiency Anemia
Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy
Anaemia and functional iron deficiency are common conditions in patients with lymphoid malignancies, conditions which reduce significantly the quality of life and increase morbidity and mortality.
- Trial name
- FID-CHEMO (NCT01101399)
- Testing
- Ferric carboxymaltose
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 19 people
- Sponsor
- Vifor Pharma
Non-Small Cell Lung Cancer, Colorectal Cancer
Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
An interventional, prospective clinical performance study protocol, for the testing of DNA extracted from tumor tissue biopsy samples, using the therascreen® KRAS RGQ PCR Kit, from patients with Non-Small Cell Lung Cancer and…
- Trial name
- NCT05348187
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 309 people
- Sponsor
- QIAGEN Gaithersburg, Inc
No Condition
Performance Thresholds Evaluation by Wet Injection Quantification and Magnetic Resonance Imaging (MRI) of Subcutaneous and Intramuscular Injections (0,65ml) of Several Configurations of Needle-free Devices (ZENEO®)
The aim of this study is to evaluate the performance of the ZENEO needle free device in subcutaneous functioning limits (low performance limit and high performance limit) and for intramuscular injections.
- Trial name
- NCT03044301
- Testing
- Intramuscular ZENEO® injection, Subcutaneous high ZENEO® injection, Subcutaneous low ZENEO® injection
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Crossject
Intermittent Claudication
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
- Trial name
- NCT00403494
- Testing
- Sapropterin Dihydrochloride
- Where
- 20 sites in United States, Argentina
- Volunteers
- 190 people
- Sponsor
- BioMarin Pharmaceutical
Pancreatic Cancer
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.
- Trial name
- NCT00044031
- Testing
- G17DT Immunogen
- Volunteers
- 394 people
- Sponsor
- Cancer Advances Inc.
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
The purpose of this research was to assess the absolute and relative incidence of acute pancreatitis in persons initiating exenatide compared with persons initiating a different antidiabetic agent, and secondarily, persons…
- Trial name
- NCT01077323
- Testing
- exenatide, Other antidiabetic therapies, No diabetes therapy
- Where
- United States
- Volunteers
- 363,766 people
- Sponsor
- AstraZeneca
Patients With Pace Makers But no Evidence of Ischemic Heart Disease
A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
To assess the effects of GTN on QT and QTc in subjects with And without atrial pacing. This will be done with and without autonomic blockade at two different pacing rates.
- Trial name
- NCT00174512
- Testing
- GTN, Moxifloxacin
- Where
- 6 sites in Belgium, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Pfizer
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Gaucher Disease
Taste Evaluation of Different Liquid Formulations With Eliglustat
Primary Objective: The purpose of this study is to assess the palatability of eliglustat prototype liquid formulations in healthy subjects.
- Trial name
- NCT02422654
- Testing
- eliglustat
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company